Boundless Bio (BOLD) Q1 2026 earnings summary

Executive summary

• Focused on developing ecDNA-directed therapeutics (ecDTx) for oncogene amplified cancers, with lead candidate BBI-940 in Phase 1 clinical trial (KOMODO-1) for ER+/HER2- and TNBC-LAR breast cancer patients who progressed after CDK4/6 inhibitor and endocrine therapy as of Q1 2026.

• Advanced enrollment in KOMODO-1 and presented preclinical data at AACR 2026 showing BBI-940's anti-tumor activity and tumor regression in multiple ecDNA+ cancer models.

• Streamlined operations by prioritizing BBI-940, winding down other programs, and restructuring facilities, including terminating a long-term lease and moving to a smaller space.

• No products approved or revenue generated to date; expects continued losses and need for additional funding.

Financial highlights

• Net loss of $13.6 million for Q1 2026, improved from $15.8 million in Q1 2025, driven by lower R&D and G&A expenses.

• R&D expenses were $9.7 million and G&A expenses were $4.7 million for Q1 2026, both down year-over-year.

• Operating expenses decreased to $14.5 million from $17.3 million year-over-year, mainly due to reduced personnel and program costs.

• Cash, cash equivalents, and short-term investments totaled $92.8 million as of March 31, 2026, expected to fund operations into the second half of 2028.

• Accumulated deficit reached $273.2 million as of March 31, 2026.

Outlook and guidance

• Existing cash runway expected to fund operations into the second half of 2028, assuming current operating plan.

• Initial safety and efficacy clinical proof-of-concept data for BBI-940 anticipated within the current cash runway.

• Additional funding will be required for long-term operations and potential commercialization.